Skip to main content
Premium Trial:

Request an Annual Quote

Michael Callaghan, Mark Smedley, Victor Ambros

Premium
Michael Callaghan has resigned from Vermillion’s board of directors, the company stated in a filing with the US Securities and Exchange Commission last week.
 
Callaghan was a member of the company’s audit and compensation committees. The company said he resigned for personal reasons and not as the result of any disagreement.
 

 
Invitrogen announced that it has named Mark Smedley, the firm’s global head of operations, to lead the integration team for its $6.7 billion acquisition of Applied Biosystems.
 

 
RXi Pharmaceuticals has appointed University of Massachusetts scientist Victor Ambros to its scientific advisory board. Ambros is best known for his work in discovering microRNA. He was a professor at Dartmouth College from 1992 to 2007, and before that he studied genetic pathways as a post-doctoral fellow at the Massachusetts Institute of Technology.

Filed under

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.